Kendall Law Group Investigates HealthTronics, Inc. Merger for Shareholders

Kendall Law Group is investigating HealthTronics, Inc. (NASDAQ: HTRN) for shareholders in connection with the proposed sale of the Company to Endo Pharmaceuticals Holdings Inc. The national securities firm seeks to determine whether HealthTronics and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are an HTRN shareholder and have information to contribute or would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [e-mail].

On May 5, 2010, HealthTronics announced that they had entered into an agreement to be acquired by Endo for $223 million. According to the agreement, HTRN shareholders will receive $4.85 per share. HTRN stock traded between $4.19 and $4.50 prior to the economic downturn in the latter part of 2008 and has experienced steady growth since then. President and CEO, James Whittenburg recently cited improvements in earnings in the fourth quarter of 2009. The company also touted “continued reinvestment into growth initiatives” and anticipated “meaningful organic growth in 2011 and beyond.” Shareholders are encouraged to contact Kendall Law Group as the tender offer is expected to expire by July 1, 2010.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in dozens of merger and acquisition cases nationwide, including some of the largest transactions in the United States.